VJHemOnc is committed to improving our service to you

ASH 2019 | FT596: iPSC-derived CAR-NK cells with engineered persistence for B-cell malignancies

VJHemOnc is committed to improving our service to you

Bahram Valamehr

Bahram Valamehr, PhD, Fate Therapeutics Inc., San Diego, CA, discusses the multi-antigen targeted CAR-iNK (iPSC derived natural killer) cell immunotherapy for B-cell malignancies as a monotherapy and in combination with monoclonal antibody therapy such as rituximab, FT596. This engineered immune cell is consistently manufactured from a master iPSC line engineered to uniformly express an NK cell-calibrated CD19-targeting CAR, an enhanced functioning high-affinity, non-cleavable CD16 (hnCD16) and a recombinant fusion of IL-15 and IL-15 receptor alpha (IL-15RF) for cytokine-autonomous persistence. Studies performed demonstrated FT596 provides a multi-antigen targeting, potent and persistent engineered immune cell. This press briefing was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter